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ABSTRACT 
Aim: To find out a prophylactic drug for migraine having better efficacy and minimal side effects. To compare the efficacy of Propranolol Vs. 
Amitriptyline as prophylactic agent for migraine. 
Material and Methods: This was a prospective, comparative, parallel, double blind, randomized clinical trial. As per the ICHD III beta 
diagnostic criteria for migraine. Included subject aged between 5-65 years. A total of 126 patients were enrolled in the study, diagnosed cases of 
migraine were randomly allocated using random number table to either Group 1 (Period 1: To receive tablet Propranolol 4–16 weeks and 
Period 2: Amitriptyline 20–32 weeks) or Group 2 (Period 1: To receive tablet Amitriptyline 4–16 weeks and Period 2: Propranolol 20–32 
weeks). Patients were recorded in a headache diary the number of migraine attacks, the duration of attacks in hours and the severity.  
Result: In both the groups, maximum number of patients were in the age group of 5-25 years and least number of patients were 46-65 years of 
age. The mean Frequency of Attack of migraine in Group 1 at period 1 was 4.41±1.22 and period 2 was 4.01±0.92. In Group 2 during period 1 
was 3.93 ±0.97 and in period 2 mean 4.21 ±1.02. The mean severity of Attack of migraine in Group 1 at period 1 was 2.91 ±0.84 and period 2 
was 2.11 ±0.64. In Group 2 during period 1 was 2.03 ±0.71 and in period 2 mean 2.76 ±0.81. The mean duration of Attack of migraine in Group 
1 at period 1 was 16.01 ±2.60 hours and period 2 was 13.51 ±2.22. In Group 2 during period 1 was 13.63 ±1.56 and in period 2 mean 15.83 
±2.00. These were statistically significant difference in Group 1 and Group 2. 
Conclusion: This trial shows that Amitriptyline is superior effective compare with propranolol but propranolol is well tolerated as compared 
with amitriptyline in migraine prophylaxis.   
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INTRODUCTION:  
A migraine is a primary headache disorder characterized by 
recurrent headache that are moderate to severe. Typically, 
the headaches affect one half of the head, are pulsating in 
nature, and last from two to 72 hours.(1) Associated 
symptoms may include nausea, vomiting, and sensitivity to 
light, sound, or smell.(2)  The pain is generally made worse by 
physical activity.  Up to one-third of people have an aura: 
typically, a short period of visual disturbance that signals 
that the headache will soon occur. (3)  Occasionally, an aura 
can occur with little or no headache following it. (4)  
Migraines are believed to be due to a mixture of 
environmental and genetic factors.(5)  About two-thirds of 
cases run in families.(6)  Changing hormone levels may also 
play a role, as migraines affect slightly more boys than girls 
before puberty and two to three times more women than 
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men.(7)  The risk of migraines usually decreases during 
pregnancy.(8)  A number of psychological conditions are 
associated, including depression, anxiety, and bipolar 
disorder, as are many biological events or triggers.(9)  
Whereas, the underlying mechanisms involve the nerves and 
blood vessels of the brain.(10)  Some evidence supports a 
primary role for central nervous system structures (such as 
the brainstem and diencephalon), while other data support 
the role of peripheral activation (such as sensory nerves that 
surround blood vessels of the head and neck).(11,12)  The 
potential candidate vessels include dural arteries, pial 
arteries and extracranial arteries such as those of the scalp. 
The role of vasodilatation of the extracranial arteries, in 
particular, is believed to be significant. (13)   
Furthermore, Classification of these migraine disorders is 
included in the International Classification of Headache 
Disorders (ICHD), third edition, published in 2013. (14) 
Headaches are classified into primary and secondary types. 
Migraines are tension-type headaches are the most common 
of the primary headache disorders. (15) Migraine disorders 
are further classified into migraine without aura, migraine 
with aura, familial or sporadic hemiplegic migraine, and 
basilar-type migraine. Complications of migraines include 
chronic migraine, status migrainosus, and persistent aura 
without infarction, migrainous infarction, and migraine-
triggered seizures. (16) 
Treatments of migraines include medications, nutritional 
supplements, lifestyle alterations, and surgery. Prophylaxis is 
recommended in those who have headaches more than two 
days a week, cannot tolerate the medications used to treat 
acute attacks, or those with severe attacks that are not easily 
controlled.(17) The goal is to reduce the frequency, 
painfulness, and/or duration of migraines, and to increase 
the effectiveness of abortive therapy.(18)Another reason for 
prevention is to avoid medication overuse headache. This is a 
common problem and can result in chronic daily 
headache.(19)Prophylaxis of migraine medications are 
considered effective if they reduce the frequency or severity 
of the migraine attacks by at least 50%.(20) Guidelines are 
fairly consistent in rating Topiramate, Sodium 
Valproate, Propranolol, and Metoprolol as having the highest 
level of evidence for first-line use.(21) 
Beta-adrenergic blockers, such as propranolol, are among 
the most prescribed drugs for migraine prophylaxis. (22) The 
usual propranolol doses for migraine prevention in clinical 
trials have ranged from 80 to 160 mg a day. (23) The possible 
mechanisms of action of propranolol in the prophylactic 
treatment of migraine are listed below: 
1. Blockade of these beta-adrenergic receptors results in 
inhibition of arterial dilatation. 
2. The drug may block the sticky elements of the blood, 
the platelets, from adhering together and thus releasing 
substances which cause blood vessels to constrict and 
dilate. 
3. There may be a central mechanism of action in the 
brain "turning off" the generators that cause migraine. 
(24) 
In addition to its effects on the adrenergic system, there is 
evidence that indicates that propranolol may act as a 
weak antagonist of certain serotonin receptors, namely 
the 5-HT1A, 5-HT1B, and 5-HT2B receptors. The latter involved 
in the effectiveness of propranolol in the treatment 
of migraine at high doses. (25) 
Antidepressants, especially tricyclic agents such as 
amitriptyline has been a mainstay in the prophylactic 
therapy of migraine. It can be particularly useful when co-
morbid conditions such as depression, peripheral 
neuropathy, or insomnia is present. (26) Amitriptyline inhibits 
histamine, 5-HT, and acetylcholine, Norepinephrine and 
serotonin uptake and is the only antidepressant of this class 
with established efficacy in migraine prevention. (27) Diffuse 
noxious inhibition may be enhanced through this 
mechanism. Other possible mechanisms in migraine could be 
explained by its ability to block sodium-channels; enhance 
GABA-mediated inhibition; potentiate endogenous opioids; 
and intensify descending inhibition on nociceptive pathways. 
(28) 
Hence, this study was undertaken 1. To find out a 
prophylactic drug for migraine having better efficacy and 
minimal side effects and thereby safety of these drugs 2. To 
compare the efficacy of Propranolol Vs. Amitriptyline as 
prophylactic agent for migraine and 3. To compare the safety 
of Propranolol Vs Amitriptyline as prophylactic agent for 
migraine. The study was intending to probe into the best 
medication for prophylaxis of migraine in terms of safety and 
efficacy with careful and well-planned design which can be 
translated into clinical settings for benefit of migraine 
patients.  
MATERIAL AND METHODS:  
The study was conducted in Patients with symptoms of 
Migraine attending Department of Medicine, Santosh Medical 
College & Hospital, after the approval of the Institutional 
Ethics Committee. This was a prospective, comparative, 
parallel, open-label, randomized clinical trial.  
As per the International Classification of Headache Disorders 
3rd edition-Beta version (ICHD III beta) diagnostic criteria 
for migraine were followed as: 
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Migraine without aura  Migraine with aura  Migraine in children  Chronic migraine 
A. At least five attacks 1 
fulfilling criteria B-D 
A. At least two attacks fulfilling 
criteria B and C 
A. At least five attacks 
fulfilling criteria B-D 
A. Headache (tension-type-like 
and / or migraine-like) on 15 
days per month for > 3 
months 2 and full-filling 
criteria B and C 
B. Headache attacks lasting 4-
72 hours (untreated or 
unsuccessfully treated) 
B. One or more of the following 
fully reversible aura 
symptoms: 
1. Visual 
2. Sensory 
3. Speech and / or language 
4. Motor 
5. Brainstem 
6. Retinal 
B. Headache attack 
lasting: 1-72 hours 
B. Occurring in a patient who 
has had at least five attacks 
fulfilling criteria B-D for 1.1 
Migraine without aura and / or 
criteria B and C for 1.2 
Migraine with aura 
C. Headache has at least two 
of the following four 
characteristics: 
1. Unilateral location 
2. Pulsating quality 
3. Moderate or severe pain 
intensity 
4. Aggravation by or causing 
avoidance of routine physical 
activity (e.g. walking or 
climbing 
stairs) 
C. At least two of the following 
characteristics: 
1. At least one aura symptom 
spreads gradually over 5 
minutes, and / or two or more 
symptoms occur in succession 
2. Each individual aura 
symptom lasts 5-60 minutes 
3. At least one aura symptom 
is unilateral 
4. The aura is companied, or 
followed within 60 minutes, by 
headache 
C. has at least two 
of the following four 
characteristics: 
1.Unilateral 
2. Pulsating quality 
3. Moderate to severe 
pain intensity 
4. Aggravation by routine 
physical activity 
C. On 8 days per month for > 3 
months, fulfilling any of the 
following 3: 
1. Criteria C and D for 1.1 
Migraine without aura 
2. Criteria B and C for 1.2 
Migraine with aura 
3. Believed by the patient to be 
migraine at onset and relieved 
by a triptan or ergot 
derivative 
D. During headache at least 
one of the following: 
1. Nausea and / or vomiting 
2. Photophobia and 
phonophobia 
D. Not better accounted for by 
another ICHD-3 diagnosis, and 
transient 
ischemic attack has been 
excluded. 
D. During headache 
at least one of the 
following: 
1. Photophobia and 
phonophobia 
2. Nausea or vomiting 
D. Not better accounted for by 
another ICHD- 
3 diagnoses. 
E. Not better accounted for by 
another ICHD-3 
diagnosis 
   
 
Subject aged between 5-65 years. 
The following categories of patients were excluded from the 
study: 
 Patients <5 years & >65 years. 
 Patients having chronic incapacitating illness e.g. AIDS, 
cancer, TB. 
 Patients whose primary headaches are other than 
migraine headaches. 
The patients meeting the inclusion criteria were explained in 
detail about the nature of the trial, its purpose, procedures, 
and follow-up. They were provided with detailed trial 
information in case report form. Written informed consent 
was obtained from those who volunteered to participate in 
the trial. Current medical history and diagnosis were noted 
during the first visit.  
A total of 126 patients were enrolled in the study, diagnosed 
cases of migraine were randomly allocated using random 
number table to either Group 1 (Period 1: To receive tablet 
Propranolol 4–16 weeks and Period 2: Amitriptyline 20–32 
weeks) or Group 2 (Period 1: To receive tablet Amitriptyline 
4–16 weeks and Period 2: Propranolol 20–32 weeks). During 
the first 4 weeks, the run-in period, the patients do not 
receive prophylactic treatment and have to record in a 
headache diary the number of migraine attacks, the duration 
of attacks in hours and the severity. The severity shall be 
graded on 1–3 scale: 
(1) able to work throughout the attack; 
(2) unable to work, but not staying in bed;  
(3) staying in bed. 
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 Follow-up visits shall be 4, 16, 20, and 32 after start of 
study.  
 Evaluations done by a psychiatrist blind to the 
treatment given. 
Statistical analysis 
All values were displayed as mean ± SD. Categorical variables 
were compared by chi-square test. Quantitative data on 
adverse-effects were analysed by using the students 
unpaired ‘t’-test for difference between means. P-value <0.05 
was taken as significant and P-value <0.001 was taken as 
highly significant, while P >0.05 was considered as 
insignificant. 
RESULTS: 
In both the groups, maximum number of patients were in the 
age group of 5-25 years and least number of patients were 
46-65 years of age. Mean age in group 1 patients were 
27.21±7.71 and in Group 2 patients were 28.01±7.65. 
There was no statistically significant difference in mean age 
of patient from Group 1 and Group 2 patients with Unpaired 
t test. 
 
Table 1: Comparison of Mean Age in Groups: 
Age-Group Group 1 Group 2 
No Percentage No Percentage 
5-25 years 37 61.6% 34 56.6% 
26-45 20 33.3% 25 41.6% 
46--65 3 5.0% 1 1.6% 
Total 60 100 60 100 
Mean±SD 27.21±7.71 years 28.01±7.65 years 
p-value 0.609 
 
Table 2: Gender difference between Group 1 and Group 2 
  Group 1 Group 2 Chi-Square test 
p=value 
n=60 (%) n=60 (%) 
Male 19 31.6 21 35.0 0.112 
Female 41 68.3 39 65.0 
Total 60 100 60 100 
The table 2 reflects that 120 migraine patients in Group 1: 19 were male (31.6%) while 41 were female patients (68.3%). In 
Group 1 consisted of 21 male patients (35%) and 39 female patients (65%). There was no statistically significant difference in 
number of patient from Group A1and Group 1 patients (0.112) when we applied with Chi-square test. 
 
Table 3: Comparison of Frequency of Attack of migraine between Group 1 and Group 2 
  Group 1 
Mean±SD 
Group 2 
Mean±SD 
p-value 
 
 
Frequency of 
Attack 
Period 1  
(Propranolol) 
Period 2  
(Amitriptyline) 
Period 1  
(Amitriptyline) 
Period 2 
(Propranolol)  
P=0.016 
4.41±1.22 4.01±0.92 3.93±0.97 4.21±1.02 
In Table 3, the mean Frequency of Attack of migraine in Group 1 at period 1 was 4.41 with SD of 1.22 and period 2 was 4.01 
with SD 0.92. In Group 2 during period 1 was 3.93 with SD of 0.97 and in period 2 mean 4.21 with SD 1.02. These was 
statistically significant difference in Group 1 and Group 2 (p=0.016) with Unpaired t test. 
 
Table 4: Comparison of severity of Attack of migraine between Group 1 and Group 2 
  Group 1 
Mean±SD 
Group 2 
Mean±SD 
p-value 
 
 
Severity of 
Attack 
Period 1  
(Propranolol) 
Period 2  
(Amitriptyline) 
Period 1  
(Amitriptyline) 
Period 2 
(Propranolol)  
P=0.023 
2.91±0.84 2.11±0.64 2.03±0.71 2.76±0.81 
In Table 4, the mean severity of Attack of migraine in Group 1 at period 1 was 2.91 with SD of 0.84 and period 2 was 2.11 with 
SD 0.64. In Group 2 during period 1 was 2.03 with SD of 0.71 and in period 2 mean 2.76 with SD 0.81. These was statistically 
significant difference in Group 1 and Group 2 (p=0.023) with Unpaired t test. 
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Table 5: Comparison of Duration of Attack of migraine between Group 1 and Group 2 
  Group 1 
Mean±SD 
Group 2 
Mean±SD 
p-value 
 
 
Duration of Attack 
(hours) 
Period 1  
(Propranolol) 
Period 2  
(Amitriptyline) 
Period 1  
(Amitriptyline) 
Period 2 
(Propranolol)  
P=0.038 
16.01±2.60 13.51±2.22 13.63±1.56 15.83±2.00 
In Table 5, the mean duration of Attack of migraine in Group 1 at period 1 was 16.01 hours with SD of 2.60 and period 2 was 
13.51 hours with SD 2.22. In Group 2 during period 1 was 13.63 hours with SD of 1.56 and in period 2 mean 15.83 hours with 
SD 2.00. These was statistically significant difference in Group 1 and Group 2 (p=0.038) with Unpaired t test. 
 
DISCUSSION 
In this study, we compared Propranolol and amitriptyline. 
Although these two drugs are first choice drugs for migraine 
prophylaxis, they are commonly used and have been shown 
to be effective. (29) In our study reduced mean frequency of 
migraine attack by Amitriptyline compared with 
Propranolol. This is somewhat similar results of Peikert et al. 
who found that Propranolol reduced the mean frequency 
attack (30) and Taubert who achieved a reduction of using an 
Amitriptyline. (31) 
Mean severity of attack of migraine was reduced higher with 
Amitriptyline compared with Propranolol in our study, 
leading us to the conclusion that Amitriptyline was superior 
to Propranolol in reducing attack severity. Similar results 
have been reported in other studies. Peikert et al. (30) also 
reported that statistical significance. This was also the fact in 
the study of Taubert where there was significant difference 
in Amitriptyline reducing attack severity, (31) though the 
results were in favour of Amitriptyline.  
We found that drug regimens, Propranolol and amitriptyline, 
are superior in reducing attack frequency and severity when 
compared with each other. The reduction in frequency and 
severity of migraine attacks was statistically significance 
when compared to each other. This trial shows that both 
drug is equally effective and well tolerated as Propranolol 
and amitriptyline in migraine prophylaxis. It could be a new 
treatment option, especially for patients in whom other 
established drugs are contraindicated, not tolerated or 
ineffective. As this is the only comparative trial of 
Propranolol in migraine prophylaxis so far and our numbers 
are small, more and larger comparative trials with 
Propranolol and amitriptyline, also comparing first choice 
drugs like beta-blockers, are needed. The ideal drug for 
migraine prophylaxis however, a drug that is highly effective 
in reducing attack frequency but has few side effects. (32) 
The mechanism of antimigraine prophylactic effects of 
amitriptyline and propranolol: Evidence indicated a 
relationship between serotoninergic or adrenergic system 
and migraine. (33) A preventive migraine drug could raise 
threshold to activation of migraine process either centrally 
or peripherally. Drug could decrease activation of migraine 
generator, enhance central antinociception, rise threshold 
for spreading depression, or stabilize sensitive migrainous 
nervous system by changing serotonergic or sympathetic 
tone. (34) Some have suggested that down-regulating the 
5HT2 receptor or modulating discharge of serotonergic 
neurons involved in migraine prevention. (35) Amitriptyline 
down-regulates both 5HT2 and β-adrenergic receptors. (36) 
Propranolol can also bind to 5HT2 receptors and exert site-
selective vasoconstrictive effects via serotonergic blockade. 
(37) This drug is also believed to reduce stress-induced 
release of serotonin from platelets. (38) It should be 
considered that undoubtedly there are more than one 
mechanism involved in migraine attacks and preventive 
drug also most likely work by more than one mechanism of 
action. (39)  
Different profile of results in two phases of propranolol and 
amitriptyline, might be related to different mechanisms of 
actions of these two drugs. (40) It has been claimed that 
prevention of migraine attacks by early treatment of acute 
migraine headaches or prophylactic management of 
headaches might minimize headache recurrence. (41) This 
hypothesis is strengthened by results of propranolol and 
amitriptyline. However, the frequency, severity and duration 
of migraine attacks in both groups were statistically 
significant compared to the intergroup and intragroup 
comparison. These results approve hypotheses that 
prevention of migraine attacks reduces headache recurrence 
with Amitriptyline. Propranolol drug has fewer side effects 
as may consider this drug as a preferred drug for migraine 
treatment.  
This study has several limitations. The number of patients 
who completed the study in two groups was too small, so 
that the conclusions on the effectiveness of these treatments 
must be interpreted very cautiously. In addition, the follow-
up time of patients in the therapy phase was only of 32 
weeks for titration of doses. Future studies evaluating the 
association of drugs in patients with migraine and patients 
with chronic migraine should include a larger number of pa-
tients and should follow patients for at least six months 
using the drugs. Another limitation is that the symptomatic 
medications were not registered in the pretreatment and 
treatment phases. However, despite these limitations, this 
study points to some data that should be taken into account 
in future drugs studies. First, the use of beta blockers, at 
doses below those used in previous therapeutic trials that 
used 80 to 160 mg per day of propranolol, was effective. 
Therefore, low beta blockers doses in combination with 
antidepressants or other types of drugs may be used in 
future studies. Second, the combination of these drugs did 
not result in higher intolerance or more frequent side 
effects, suggesting that further studies with combination of 
drugs can be safely carried out. 
CONCLUSION: 
Pharmacological preventive treatment of migraine and 
chronic migraine is a major challenge. The use of a single 
drug has been widely studied, but the combination of drugs 
could theoretically have advantages, since different 
substances act on different targets of the pathophysiology of 
the disease. Although this study has provided evidence of the 
therapeutic efficacy of Propranolol and amitriptyline, these 
substances showed to be safe and well tolerated. Further 
studies using this and other combinations of substances, in 
larger groups of patients, in higher doses, and for a longer 
period of time, may help to clarify the role of combined 
therapy in the treatment of migraine. 
This trial shows that Amitriptyline is superior effective 
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compare with propranolol but propranolol is well tolerated 
as compared with amitriptyline in migraine prophylaxis.  
The ideal drug for migraine prophylaxis is Amitriptyline, 
highly effective in reducing frequency, severity and duration 
of attack but propranolol has few side effects. When 
migraine with depression, anxiety disorders, irritable bowel 
syndrome and epilepsy are comorbidities of migraine for 
amitriptyline. When migraine and hypertension and/or 
angina occur together, propranolol might be drug of choice. 
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